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Background. Neoangiogenesis is crucial in plaque progression and instability. Previous data from our group showed that Nestin-
positive intraplaque neovessels correlatedwith histological complications.The aimof the present work is to evaluate the relationship
between neoangiogenesis, plaque morphology, and clinical instability of the plaque.Materials and Methods. Seventy-three patients
(53 males and 20 females, mean age 71 years) were consecutively enrolled. Clinical data and 14 histological variables, including
intraplaque hemorrhage and calcifications, were collected. Immunohistochemistry for CD34 and Nestin was performed. RT-PCR
was performed to evaluate Nestin mRNA (including 5 healthy arteries as controls). Results. Diffusely calcified plaques (13/73)
were found predominantly in females (𝑃 = 0.017), with a significantly lower incidence of symptoms (TIA/stroke (𝑃 = 0.019)
than noncalcified plaques but with the same incidence of histological complications (𝑃 = 0.156)). Accordingly, calcified and
noncalcified plaques showed similar mean densities of positivity for CD34 and Nestin. Nestin density, but not CD34, correlated
with the occurrence of intraplaque hemorrhage. Conclusions. Plaques with massive calcifications show the same incidence of
histological complications but without influencing symptomatology, especially in female patients, and regardless of the amount of
neoangiogenesis.These results can be applied in a future presurgical identification of patients atmajor risk of developing symptoms.
1. Introduction
The vulnerable atheromatous plaques have been originally
described as characterized by a large lipid core, a thin
fibrous cap, a rich infiltrate of macrophages, and little
smooth muscle cell component [1]. Neoangiogenesis began
to stand out as one of the most important pathological
processes involved in the plaque progression only in the
recent years [2], when neovessel formation was related to an
increased plaque vulnerability and to the onset of clinical
symptoms [3, 4]. In particular, the intraplaque hemorrhage
and the incidence of symptomatic plaques were directly
related to the neovessel density, simply measured by means
of immunohistochemistry (IHC) for CD34 [3]. If the density
of neovessels is likely to be directly relatedwith plaque growth
and progression [5], the morphology of the neoangiogenetic
structures plays a key role in the onset of the plaque instability.
In fact plaque neovessels are reported to lack extracellular
junctions [6]; moreover, symptomatic plaques show larger
and more irregular neoangiogenetic structures compared to
the neovessels of asymptomatic plaques [7]. Recently we
described the IHC and immunofluorescence positivity for
Nestin and WT1 in vasa vasorum from healthy arteries,
hypothesizing that they might represent the starting point of
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the neoangiogenesis during atherosclerosis [8]. Afterwards
we actually confirmed the expression of Nestin and WT1
in diseased arteries but together with the observation that
nearly 36% of the neovessels showed positivity for Nestin and
negativity forWT1 (Nestin+/WT1−). As amatter of fact, hem-
orrhagic plaques showed significantly more Nestin+/WT1−
neoangiogenesis than uncomplicated plaques at both IHC
and RT-PCR [9].
The aims of the present study were (i) to evaluate
the relationship between the intraplaque neoangiogenesis
(as quantified by CD34 and Nestin IHC) and the main
histopathological plaque characteristics (especially complica-
tions and calcifications) and (ii) to evaluate the relationship
between the immunohistochemical and histopathological
characteristics and the clinical plaque instability.
2. Materials and Methods
2.1. Patients and Clinical Data. This study was carried out
in conformity to the ethical guidelines of the 1975 Decla-
ration of Helsinki (and following modifications); informed
consent was obtained from all patients before surgery. We
evaluated all consecutive cases of carotid endarterectomy
specimens that came to our Surgery Unit in 2 years, from
January 2011. According to the European Society for Vas-
cular Surgery (ESVS) and the Society of Vascular Surgeons
(SVS) recommendations [11, 12], the patients were submitted
to carotid endarterectomy (CEA) for either symptomatic
carotid plaques ≥50% or asymptomatic carotid stenosis
≥70%. For each patient the following clinical data were col-
lected: occurrence of symptoms related to the carotid disease,
that is, transient ischemic attack (TIA) and stroke, association
with chronic ischemic cardiopathy, chronic obstructive bron-
chopneumonia and/or chronic renal failure, smoke, diabetes,
dyslipidemia, and therapy with acetylsalicylic acid or statins.
2.2. Histopathological Analysis. Endarterectomy specimens
were sent to our Pathology Unit, fixed in formalin, routinely
processed, and paraffin embedded. Two 𝜇m thick slices were
cut from the paraffin blocks for haematoxylin-eosin and
trichrome stains. For each case, the following histopatholog-
ical features were collected as single variables, as previously
reported [9]: the occurrence of intraplaque complications
(hemorrhage, thrombosis, and/or surface defects) which
put the plaque into the AHA type VI [10], maximum and
minimum size of the fibrous cap, extension of the lipid core,
and extension of the inflammatory infiltrate. For the purposes
of the study, the amount of calcifications was assessed and
graded from 0 to 4+ in relation to their extension along
the vessel circumference; the intraplaque calcification was
therefore simplified in low-grade (if 0 to 2+) and high-grade
(if 3+ or 4+).
2.3. Immunohistochemistry. Themonoclonal antibodies used
in this study are listed in Table 1. Immunohistochemistry
(IHC) for Nestin was performed manually, as previously
described [8, 9]. IHC for CD34 was performed automatically,
Table 1: Technical characteristics of the antibodies used for
immunohistochemistry.
Antibody Clone Manufacturer
Nestin 10C2 (mouse IgG) Millipore
CD34 QBEnd/10 (mouse IgG) Roche Ventana
bymeans of Benchmark XT (VentanaMedical System), using
the XT ultraView DAB v3 program.
The microvessel “density of positivity” [9] for Nestin
was evaluated after the identification of specific Regions
of Interest (ROI). ROI were defined as areas with CD34-
positive neoangiogenesis, and at 20x magnification each ROI
was divided into 1 mm2 fields using an Olympus ocular
micrometer (1 length unit = 5 𝜇m, which means that an area
of 100 × 100 units is equal to 0.25mm2). Firstly, CD34 and
Nestin microvessel positivity were counted separately; the
Nestin-positive vessels were counted in the same ROI where
CD34 was evaluated. Afterwards we calculated the “density
of positivity” for CD34 and Nestin by dividing the sum of all
the positive vascular structures observed by the number of
the counted fields in each section. Finally we calculated the
ratio between the densities of positivity of Nestin and CD34
in each case: the Nestin/CD34 ratio represents how many
CD34-positive neovessels concomitantly express Nestin in
the intraplaque neoangiogenesis.
2.4. RT-PCR. Reverse Transcriptase-Polymerase Chain
Reaction (RT-PCR) for the product of the Nestin gene
was carried out on 5 type V and on 5 type VI plaques, in
order to evaluate the different expression in complicated
and uncomplicated carotid plaques. A pool composed of
5 healthy carotid arteries was used as controls. Healthy
carotids were kindly provided by the Cardiovascular Tissue
Bank of S. Orsola-Malpighi University Hospital of Bologna
from 5 multiorgan donors (3 males and 2 females, mean
age 33.8 ± 13.2 years, range 18–53 years), without known
comorbidities.
Tissues were homogenized with an Ultraturax and incu-
bated with 800 ul of Trizol reagent (TRIzol Life Technologies,
Carlsbad, CA, USA) for 5min at RT. RNA extraction with
Trizol was performed following manufacturer instructions.
RNA quality and concentration were measured by using an
ND-1000 spectrophotometer (NanoDrop,ThermoFisher Sci-
entific, Wilmington, DE, USA). Reverse transcription assay
was performed using 2.0𝜇g of starting total RNA quantity
per 25 𝜇L ofmix, following themanufacturer’s protocol (High
capacity cDNA Archive kit, Life Technologies). The cDNA
was stored at −20∘C until RT-PCR was performed. RT-
PCR was carried out following MasterMix TaqMan Protocol
(TaqMan Univ PCR MasterMix, Life Technologies). Four
𝜇L of neat cDNA was amplified using specific probes for
Nestin (NC 000001.10) and GUSB (NM 000181.3) in the RT-
PCR mix (TaqMan Gene Expression Assay, Life Technolo-
gies, respective ID assay: Hs04187831 g1, Hs00939627 m1).
Reactions were run on ABI PRISM 7900HT Sequence Detec-
tion System (Life Technologies). Cycling conditions were as
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Chronic ischemic cardiopathy 25 34.2%
Chronic obstructive pulmonary Disease 4 5.5%
Chronic renal failure 4 5.5%
Acetylsalicylic acid use 64 87.7%
Statins use 42 57.5%
follows: 10min at 95∘C, 50 cycles at 95∘C for 15 s, and 60∘C
for 60 sec. Each assay was carried out in triplicate and the
transcription level was normalized using GUSB as a reference
gene.
2.5. Statistical Analysis. All statistical analyses were carried
out with SPSS software for Windows, version 20. All contin-
uous variables are expressed as means, standard deviations,
and ranges; all categorical variables (both nominal and
ordinal) are expressed as number of cases and percentages.
The Spearman test, the chi-square test, the Mann-Whitney𝑈
test, and the Kruskal-Wallis test were used when appropriate.
The mRNA expression values for atheromatous type V and
type VI plaques are presented as fold expression in relation to
healthy arteries; the actual values were calculated using the
2
−ΔΔCT equation, where ΔΔCT = [CT Target − CT GUSB]
(atheromatous sample V or VI) − [CT Target − CT GUSB]
(healthy sample). RT-PCR data were analyzed assuming the
null hypothesis that the CT differences between target and
reference genes will be the same in type V tissue versus type
VI tissue. If the null hypothesis is not rejected, then the
ΔΔCT would not be significantly different from 0. Analyses
of differences between the three groups (healthy, class V, and
class VI plaques) were performed with one-way ANOVA
test, followed by Tukey’s test. All the 𝑃 values are derived
from testing the null hypothesis that ΔΔCT are equal to 0
(at 𝑃 = 0.05). SEM, SD, and the confidence interval (CI) of
2
−(ΔΔCT) are all derived from the SEM, SD, and CI of ΔΔCT
as explained by Yuan et al. [13].
3. Results
3.1. Patients and Histopathological Analysis. Seventy-three
patients were finally enrolled, 53 (72.6%) males and 20
(27.4%) females, with a mean age at the time of endarterec-
tomy of 70.8 ± 8.7 years (range 42–86 years). The clinical
characteristics of the patients, including ongoing therapy, are
summarized in Table 2. Notably, 29 (39.7%) plaques were
symptomatic, since 11 (15.1%) patients had a stroke as clinical
presentation and 18 (24.6%) had a transient ischemic attack
(TIA).
At histopathological analysis, mean maximum cap size
was 1132.8 ± 485.6 𝜇m (range 120–2500𝜇m) and mean
minimum cap size was 284.3±199.7 𝜇m (range 40–1125 𝜇m);
the lipid core was not evident in 8 (11.0%) cases, 1/4 in
16 (21.9%), 2/4 in 18 (24.7%), 3/4 in 23 (31.4%), and 4/4
in 8 (11.0%); the inflammatory infiltrate was mild/focal or
absent in 14 (19.2%) cases, moderate in 20 (27.4%) cases, and
severe/diffuse in 39 (53.4%) cases. Fifty-two (71.2%) plaques
were classified as AHA type VI [10]: the most common
complication observed was intraplaque hemorrhage, present
in 41 cases, followed by endothelial erosion in 22 cases and
thrombosis in 4 cases. Eight (11.0%) further noncomplicated
plaques were classified as type VII due to the prevalently
calcified core in 8 (11.0%) cases, while the remaining 13 (17.8%)
cases were classified as type VIII (prevalently fibrotic core) or
type V (fibroatheroma) [10].
Intraplaque calcifications were graded 0 in 11 (15.1%)
cases, 1+ in 21 (28.8%), 2+ in 20 (27.4%), 3+ in 16 (21.9%), and
4+ in 5 (6.8%). According to this semiquantitative assessment
of the calcification extent, low-grade calcifications (up to
2+) were recorded in 52 (71.2%) plaques, and high-grade
calcification (3+ and 4+) was recorded in 21 (28.8%) plaques
(Figure 1).
Finally, according to the occurrence of intraplaque com-
plications and/or calcifications, our cases were sorted in
noncalcified complicated plaques (type VI-nc, 𝑁 = 39),
calcified and complicated plaques (type VI-c 𝑁 = 13),
calcified noncomplicated plaques (type VII, 𝑁 = 8), and
noncalcified noncomplicated plaques (types V–VIII, 𝑁 =
13). No correlations were found between plaque morpholog-
ical criteria used in the present study (i.e., calcifications and
histological complications) and the occurrence of chronic
ischemic cardiopathy, chronic obstructive bronchopneumo-
nia, chronic renal failure, smoke, diabetes, hypertension,
dyslipidemia, or therapy with acetylsalicylic acid or statins
(data not shown, chi-square test).
3.2. Nestin-Positive Neoangiogenesis. Two cases had no
appreciable intraplaque neoangiogenesis after IHC for CD34.
In the remaining 71 cases, the mean density of positivity for
CD34 was 10.1 ± 3.9 structures/field (range 3.5–22.1/field).
The mean density of positivity for Nestin, evaluated in the
same ROI, was 6.8±3.7 structures/field (range 1.4–18.5/field).
Themean Nestin/CD34 ratio was 0.7± 0.2, which means that
70% of the CD34-positive neovessels examined coexpressed
Nestin.This result is in line with what is previously described
[9].
The total amount of neoangiogenesis, expressed as CD34-
positive vessels, was not significantly different between type
VI plaques and uncomplicated plaques (𝑃 = 0.111, Mann-
Whitney𝑈 test), while the density of Nestin-positive neoves-
sels was significantly higher in type VI (𝑃 = 0.015, Table 3).
The calcified plaques (including complicated and uncom-
plicated) showed overall less neoangiogenesis,measuredwith
both CD34 andNestin, than noncalcified plaques (𝑃 < 0.001,
Table 3; Figure 2).
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(a) (b)
Figure 1: Details of two cases of carotid plaque with low-grade calcification (a) and high-grade calcification (b), respectively. Haematoxylin-
eosin stain, magnification 10x.
Table 3: Densities of positivity of intraplaque neovessels for CD34 and Nestin in our series of plaques, sorted by calcification and by the
occurrence of complications.
Noncalcified plaques Calcified plaques Complicated plaques Uncomplicated plaques
CD34 density 11.19 ± 3.84 7.52 ± 3.09 10.68 ± 3.79 8.99 ± 4.13
Mann-Whitney 𝑃 < 0.001 𝑃 = 0.111
Nestin density 7.69 ± 3.77 4.59 ± 2.31 7.45 ± 3.71 5.31 ± 3.09
Mann-Whitney 𝑃 < 0.001 𝑃 = 0.015
At RT-PCR, the totalmean extractedmRNA fromhealthy
tissue and typeV and typeVI plaques was 8764 ng, 5069.4 ng,
and 2172 ng, respectively.Themean CT values of endogenous
control GUSB were 36.28±0.21 in healthy tissue, 31.36±0.32
in type V plaques, and 34.20 ± 0.22 in type VI plaques. Mean
CT for tested gene Nestin were 33.04 ± 0.06 in healthy tissue,
32.37 ± 0.12 in type V plaques, and 34.21 ± 0.30 in type
VI plaques. ΔΔCT Nestin was significantly different from 0
(𝑃 = 0.0001); thus the null hypothesis was rejected, which
indicated a change in Nestin gene expression among healthy,
type V and type VI plaques. In type V and type VI plaques,
the mean ΔΔCT Nestin was, respectively, 4.25 and 3.25; this
corresponds to 2−(ΔΔCT) of 0.05 for Nestin gene expression
in type V plaques and 0.11 in type VI plaques. The type VI
plaques showed a 2-fold expression increase for Nestin gene
compared to type V plaques, as a confirmation of the IHC
results (Figure 3).
These data confirm that Nestin-positive neoangiogenesis,
studied both on the protein (IHC) and the mRNA level (RT-
PCR), plays a key role in the development of intraplaque
complications and that plaques with massive calcifications
generally have a minor density of neoangiogenesis compared
to other plaques.
3.3. Intraplaque Calcifications and Clinical Stability. Despite
the differences in neoangiogenesis, the incidence of histo-
logical complications did not differ significantly between
calcified and noncalcified plaques (𝑃 = 0.167, chi-square test;
Figure 4).
As for the clinical presentation, unsurprisingly, 25 out of
29 (86.2%) symptomatic patients (i.e., with stroke or TIA) had
a type VI plaque, versus 27 out of 44 (61.4%) asymptomatic
patients (𝑃 = 0.026, chi-square test). Interestingly, among
the 21 patients with calcified plaques, only 4 (19.0%) had
symptoms at the onset, regardless of the occurrence of
histological complications; conversely 25 out of 52 (48.1%)
patients with noncalcified plaques were symptomatic (𝑃 =
0.019, chi-square test).
The patients’ gender was correlated with the plaque
morphology and instability as well; first of all only 3 (15.0%)
of the 20 female patients in our study were symptomatic
versus 26 (49.1%) out of 53 males (𝑃 = 0.007, chi-square
test). All three symptomatic female patients had a type VI-nc
atheromatous lesion. Notably, a higher incidence of calcified
plaques was observed in female patients (𝑃 = 0.017): 10
(50.0%) females had calcified plaques (5 type VII and 5 type
VI-c) versus only 11 (20.8%) males (3 type VII and 8 type VI-
c).
4. Discussion
The severity and extent of calcification reflect the atheroscle-
rotic plaque burden and strongly predict cardiovascular
morbidity and mortality [14, 15]; in a relatively recent study,
no patients were found to have calcifications confined only
to the coronary or carotid beds [16]. The extent of calcifi-
cation is associated with a worse prognosis, albeit the real
impact of calcificationswithin a specific vascular pathological
district remains unclear [17]. For example, in the coronary
vessels small calcium depositions increase the probability
of atherosclerotic plaque rupture, especially on their edges,
while massive calcification seems to be associated with a


















Figure 2: Immunohistochemical staining for CD34 (a), (c), and (e) and Nestin (b), (d), and (f) in an uncomplicated noncalcified plaque
(a) and (b), a calcified plaque (c) and (d), and a complicated noncalcified plaque (e) and (f). Neoangiogenesis in uncomplicated plaques is
generally Nestin-negative. The overall neoangiogenesis in calcified plaques (complicated or not) is generally lower (both CD34 and Nestin)
than in complicated plaques. Magnification 20x.
decreased risk [17, 18]. Anyway, vascular calcification is
considered aworsening factor, probably due to its coexistence
with the general risk factors; a study by Iribarren et al.
[19] found that aortic arch calcification was associated with
coronary heart disease risk both in men and in women.
Thus aortic arch calcification may reflect the general burden
of disease or be a marker of more aggressive disease. At
any chance, the clinical impact of a plaque in which both
calcification and histological complications coexist is far from
being clarified.
Our aims were to evaluate the relationship between
the intraplaque neoangiogenesis, the main histopathological
characteristics (histological complications and calcifications),
and the clinical plaque instability. For these purposes, neoan-
giogenesis was evaluated and semiquantified by CD34 and
Nestin IHC, followed by RT-PCR. The majority of tissue
obtained from endarterectomy was used for the routine
histological diagnosis of surgical specimens. The remaining
tissue had to be fully processed for RT-PCR andWestern blot
analysis was not included in our protocol. However, in our
experience [8, 9] we observed that Nestin staining in IHC
is very reliable, allowing us to evaluate its cell location and
its expression at a protein level as well, without the need of
the more sensible immunoblot techniques. The correlation






















Figure 3: Difference in Nestin mRNA expression between type V (uncomplicated) and type VI (complicated) plaques (∗𝑃 < 0.001).
(a) (b)
Figure 4: An example of calcified plaque with histopathological complications (i.e., hemorrhage) with haematoxylin-eosin stain (a). The
trichrome stain highlights the hemorrhagic foci (in red (b)). Magnification 10x.
between IHC and RT-PCR confirmed that there is a direct
relationship between Nestin protein and mRNA.
According to our data calcified plaques show less inflam-
matory infiltrate, a smaller lipid core, and less neoangiogen-
esis than other plaques, but with the same incidence of hem-
orrhage, thrombosis, and surface defects, which define the
plaque as histologically complicated [10]. Yet, interestingly, in
these calcified plaques complications are not correlated with
clinical plaque instability (evaluated as symptomatology);
indeed, the incidence of TIA/stroke in patients with calcified
plaques was sensibly lower than patients with noncalcified
plaques, despite the same incidence of intraplaque com-
plications. This is noteworthy, since at least in the carotid
district the presence of calcifications seems to imply a sort
of clinical “protection” to complications, making the histo-
logical complications play second fiddle. For these reasons,
in our opinion, these plaques can be classified among the
type VII plaques, instead of type VI, at least on clinical
grounds. Alternatively, they can be classified as type VI, but
the extension of the calcifications should be stated in the
pathological report, to highlight their protective nature.
The reason why in the massively calcified plaques the
neoangiogenesis and the histological complications do not
affect symptomatology remains unclear, but it is possible that
the hemorrhages and erosions found in these plaques might
have a different pathogenesis. For example, it is possible that
they can be due directly by the mechanical stresses of the
calcified mass and not by immature neoangiogenesis and
endothelial damage. Another possible explanation is that the
“calcified type VI” plaques can represent an early stage of type
VII plaques, in which the regressive process is more recent,
and the complications have not disappeared yet (Figure 5).
The last result that emerged from our data is that 50%
of the female patients had calcified plaques, showing a sig-
nificantly lower incidence of symptoms and type VI plaques
than themale patients. Ten years ago, Allison et al. have found
53% and 30% prevalence of “zero calcification” in female and
male patients, respectively, before age of 50; after that age
the prevalence of a diffuse vessel calcification increases, in
a linear fashion in males and exponentially in females [16].
Actually, female sex hormones play an important role in bone
tissue metabolism, increasing bone density and inhibiting
osteoclast activity [20–22]. Nevertheless, it should be kept in
mind that most women in our series were postmenopausal
and their age at the moment of surgery did not differ from
males (70.2 ± 9.5 versus 71.0 ± 8.5 years), so the question














Figure 5: Flowchart illustrating the hypothetical plaque progression in relation to the Nestin-positive neoangiogenesis and calcification
features. According to AHA classification [10], type V plaque is the uncomplicated fibroatheroma, type VI is the complicated plaque, type VII
is the calcified plaque, and type VIII is the fibrotic plaque.
whether the postmenopausal hormone therapy might play
a role in the pathophysiology of the atherosclerosis is still
open.
Study Limitations. A limitation of our study is represented by
heterogeneity in the sample size of each plaque group (e.g.,
8 cases of type VII plaques were available). However, this
is a monocentric perspective study, and our series reflects
the incidence of the different plaque types in the general
population. Moreover, the patients submitted to surgery
generally have advanced plaques, and complicated type VI
plaques are the most represented. Furthermore, there is a
discrepancy between the age of the patients with plaques and
the controls, due to obvious differences in the populations of
multiorgan donors and atheromatous patients.
5. Conclusions
In conclusion, this study confirms that the Nestin+/WT1−
phenotype characterizes the plaques with morphological
features of instability, regardless of the actual amount of the
neoangiogenesis (expressed as CD34-positive vessels). The
plaques with massive calcifications show the same incidence
of histological complications but with a lower incidence of
neurological symptoms. Female patients show amuch higher
incidence of noncomplicated or calcified plaques, receiving
de facto a sort of protection compared to male patients.
A possible indication emerging from these findings could
be a comparison between the plaque dynamic imaging and
the histological assessment of calcification, to evaluate the
possibility of a presurgical risk stratification of patients, based
on their sex, risk factors, and intraplaque calcification. The
presurgical identification of those patients at major risk of
developing stroke or brain lesions is likely to make the
priority for endarterectomy more rational.
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